IAIM
AVIR icon

International Assets Investment Management’s Atea Pharmaceuticals AVIR Stock Holding History

International Assets Investment Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$4K – 604
2021
Q1 		$4K Hold
100
– – ﹤0.01% 1826
2020
Q4 		$4K Buy
+100
New +$3.22K ﹤0.01% 1679

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

International Assets Investment Management's AVIR Position: Q2 2021 in Review

International Assets Investment Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2021, closing a stake of 100 shares — an estimated $4K sold.

International Assets Investment Management first reported a position in AVIR in Q4 2020 and held it in 2 quarters. The position peaked at $4K in Q1 2021. 103 funds tracked by Wall St. Rank hold AVIR as of Q2 2021.

  • International Assets Investment Management reported no remaining Atea Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • International Assets Investment Management sold 100 Atea Pharmaceuticals shares in Q2 2021, an estimated $4K.
  • International Assets Investment Management first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • International Assets Investment Management's Atea Pharmaceuticals position peaked at $4K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2021.

Based on International Assets Investment Management's 13F filing for Q2 2021, filed 14 Jul 2021.